Cara Therapeutics, Inc. Company Profile

19:33 EDT 22nd October 2016 | BioPortfolio

News Articles [1980 Associated News Articles listed on BioPortfolio]

Unser Setup für: Cara Therapeutics (CARA)

Rückblick: Die Aktie des Biotechnologiekonzerns Cara Therapeutics gehört zweifelsohne zu den äußerst spekulativen Aktien an der Wall Street und sollte eher von erfahrenen Anlegern in die Hand geno...

BRIEF-Cara therapeutics posts Q2 shr loss $0.48

* Cara therapeutics reports second quarter 2016 financial results

BRIEF-Cara Therapeutics reports Q1 loss per share $0.39

* Cara Therapeutics reports first quarter 2016 financial results

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q2 2016 Results - Earnings Call Transcript

Cara Therapeutics Inc's (CARA) CEO Dr. Derek Chalmers on Q1 2016 Results - Earnings Call Transcript

Enteris BioPharma's Feasibility to Licensing Partner, Cara Therapeutics, Advances ...

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, commented, "We congratulate Cara Therapeutics on the initiation of its Phase 2b clinical Read more...

BRIEF-Cara Therapeutics starts enrollment in phase 2B trial of oral CR845

* Cara Therapeutics initiates enrollment in phase 2B trial of peripherally acting kappa opioid agonist, oral CR845, in chronic pain patients

MVM closes fourth fund at $233M

MVM Life Science Partners closed its fourth fund, MVM IV, at $233 million. The firm said it will invest $15-$30 million per company in healthcare companies of all stages in the U.S. and Europe. MVM in...

PubMed Articles [495 Associated PubMed Articles listed on BioPortfolio]

Injectable biomaterials: a perspective on the next wave of injectable therapeutics.

We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...

Response #2 to Immediate Intraocular Pressure Tendency Following Intravitreal Delivery of Dexamethasone Implant; Alagöz et al. J. Ocul. Pharmacol. Ther. 32:44-49, 2016.

Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications.

Pigmentation and Macular Degeneration: Is There a Role for GPR143?

Fit for the Eye: Aptamers in Ocular Disorders.

For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...

Clinical Trials [13 Associated Clinical Trials listed on BioPortfolio]

Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans (METABORANGE).

This study evaluates the effect of intake of two orange juice varieties in healthy adults. The participants will receive "Bahia" orange juice, "Cara-Cara" orange juice or a isocaloric cont...

Beat AML Core Study

In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential ther...

Localized Therapeutics for the Treatment of Gastrointestinal Disorders II

The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.

Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics

The emergence of oral delivery in cancer therapeutics is expected to result in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treat...

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

The goal of this research study to see whether biofeedback therapy helps treat asthma, and if so, how it works. Biofeedback is a treatment method that can teach people how to control their...

Companies [4 Associated Companies listed on BioPortfolio]

CARA Therapeutics

Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has enter...

Cara Therapeutics, Inc.


Instituto de Cirugía Maxilofacial e Implantología

Me es grato darles la bienvenida a la página web del INSTITUTO DE CIRUGIA MAXILOFACIAL E IMPLANTOLOGIA.El Instituto, fundado en Mayo del 2000, tiene como objetivo el tratamiento integral médico-quir...

More Information about "Cara Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cara Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cara Therapeutics, Inc. Clinical Trials and PubMed Articles about Cara Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics, Inc. Companies in our database. You can also find out about relevant Cara Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record